IL318945A - Combination therapies for treatment of cirrhosis with portal hypertension - Google Patents

Combination therapies for treatment of cirrhosis with portal hypertension

Info

Publication number
IL318945A
IL318945A IL318945A IL31894525A IL318945A IL 318945 A IL318945 A IL 318945A IL 318945 A IL318945 A IL 318945A IL 31894525 A IL31894525 A IL 31894525A IL 318945 A IL318945 A IL 318945A
Authority
IL
Israel
Prior art keywords
cirrhosis
treatment
combination therapies
portal hypertension
portal
Prior art date
Application number
IL318945A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL318945A publication Critical patent/IL318945A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
IL318945A 2022-08-12 2023-08-11 Combination therapies for treatment of cirrhosis with portal hypertension IL318945A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263371228P 2022-08-12 2022-08-12
PCT/EP2023/072278 WO2024033519A1 (en) 2022-08-12 2023-08-11 Combination therapies for treatment of cirrhosis with portal hypertension

Publications (1)

Publication Number Publication Date
IL318945A true IL318945A (en) 2025-04-01

Family

ID=87760695

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318945A IL318945A (en) 2022-08-12 2023-08-11 Combination therapies for treatment of cirrhosis with portal hypertension

Country Status (15)

Country Link
US (1) US20240058331A1 (en)
EP (1) EP4568673A1 (en)
JP (1) JP2025526746A (en)
KR (1) KR20250044929A (en)
CN (1) CN119855594A (en)
AR (1) AR130179A1 (en)
AU (1) AU2023321653A1 (en)
CA (1) CA3264757A1 (en)
CL (1) CL2025000385A1 (en)
DO (1) DOP2025000024A (en)
IL (1) IL318945A (en)
MX (1) MX2025001713A (en)
TW (1) TW202423417A (en)
UY (1) UY40392A (en)
WO (1) WO2024033519A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260097057A1 (en) * 2024-10-09 2026-04-09 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA58494C2 (en) 1995-06-07 2003-08-15 Зенека Лімітед N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical composition, process for preparing thereof and method for endothelin influence counteraction
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
EP3639827A1 (en) * 2018-10-19 2020-04-22 Noorik Biopharmaceuticals AG Use of ambrisentan for the treatment of portal hypertension and cirrhosis
WO2021014351A1 (en) * 2019-07-23 2021-01-28 Novartis Ag Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors
PH12023550025A1 (en) * 2020-07-10 2024-03-11 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease

Also Published As

Publication number Publication date
MX2025001713A (en) 2025-04-02
US20240058331A1 (en) 2024-02-22
AU2023321653A1 (en) 2025-03-27
CL2025000385A1 (en) 2025-07-04
EP4568673A1 (en) 2025-06-18
JP2025526746A (en) 2025-08-15
KR20250044929A (en) 2025-04-01
WO2024033519A1 (en) 2024-02-15
UY40392A (en) 2024-02-15
DOP2025000024A (en) 2025-05-30
CA3264757A1 (en) 2024-02-15
AR130179A1 (en) 2024-11-13
CN119855594A (en) 2025-04-18
TW202423417A (en) 2024-06-16

Similar Documents

Publication Publication Date Title
IL325744A (en) Combination therapies for the treatment of cancer
IL316706A (en) Macrocycle compounds for the treatment of cancer
IL316867A (en) Macrocyclic inhibitors of kras for the treatment of cancer
IL288522A (en) Egfr inhibitor for the treatment of cancer
SI4065585T1 (en) Substituted macrocyclic compounds and related methods of treatment
IL304595A (en) Bicyclic tetrahydroazepine derivatives for the treatment of cancer
IL315892A (en) 5-meo-dtm for the treatment of bipolar disorder
IL285999A (en) Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
IL318512A (en) Methods for the treatment of hypertension via transcranial-focused-ultrasound
IL307465A (en) Combination therapies for the treatment of cancer
IL284480A (en) Composition and methods for treatment of primary ciliary dyskinesia
IL316829A (en) Menin-mll inhibitors for the treatment of cancer
GB2605996B (en) Enhancement of treatment with immunotherapeutic agents
IL276817A (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
IL318209A (en) Therapeutic compounds and methods
IL315503A (en) Methods of treatment
CA3264757A1 (en) Combination therapies for treatment of cirrhosis with portal hypertension
IL320711A (en) Methods of treatment
IL289201A (en) Compounds for treatment of cancer
IL287213A (en) Methods for treatment of subjects with psoriatic arthritis
IL305780A (en) Methods for the treatment of cancer
GB202201824D0 (en) Methods of treatment
IL299210A (en) Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis
IL319193A (en) Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer
GB202201825D0 (en) Methods of treatment